Implandata Ophthalmic Products GmbH (Implandata) is a privately held, ISO 13485 certified medical device company founded in 2010 in Hannover/Germany.
Swisslog, a global provider of robot and data-driven intralogistics solutions, has been awarded contracts to optimize the storage and handling of medical devices from two world-leading brands in Japan.
The Mehmet Akif Ersoy Göğüs Kalp Damar Cerrahisi Eğitim Araştırma Hastanesi (IMAEH) hospital in Istanbul has joined the network of hospitals on Clinerion’s PRS platform.
CPhI Worldwide, organised by UBM, closes its 28th edition with pre-audit figures indicating a record-breaking attendance of over 44,500* and 2,598 exhibitors. Held in Frankfurt (Germany), the heart of Europe’s biggest pharmaceutical market (24-26th October, 2017), the world’s largest pharma event saw attendees from 169 countries – 25% of which are CEO or board level.
Aquila BioMedical Ltd., an innovative preclinical contract research organisation (CRO) now part of Concept Life Sciences group, has secured an extended agreement with UK-based biotech firm Macrophage Pharma Ltd. to support its preclinical immuno-oncology programmes.
Following its CPhI Europe banner headline “Enlighten your formulation”, Omya has shown how its calcium carbonates can be used to develop tailor-made products in response to specific consumer or patient needs in a variety of pharmaceutical forms.
CluePoints, a leading provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions for clinical trials, has further expanded its Late Phase work in Japan by entering into two new partnerships with global top 20 pharmaceutical companies.
Toyota Motor Corporation (Toyota) announces that it has signed an agreement with Kazusa DNA Research Institute, Eurofins Genomics K.K., and GeneBay Inc. on October 30 to license Toyota's unique GRAS-Di(1) DNA analysis technology that can dramatically accelerate selective breeding.
The largest and most recent export contract won by Priorclave is for shipment to the USA of nine research grade autoclaves which will be destined for the campus of California State University, Fullerton and will be used by faculty and students in the Department of Biological Science and Department of Chemistry and Biochemistry.
Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announced that it has begun a Phase 1b clinical program of its lead nanomedicine candidate CriPec®-docetaxel in patients with solid tumours.
Clinerion has expanded its geographic coverage to include over 60 million patients in the USA, via a strategic partnership with Provisio Inc.
NeoGenomics, Inc. , a leading provider of cancer-focused genetic testing services in the United States, announced that it has opened its first international laboratory facility in Rolle, Switzerland, in the Canton of Vaud, just outside of Geneva as a separate subsidiary, NeoGenomics Europe, S.A.
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, received the prestigious Frost & Sullivan’s 2017 European Customer Service Leadership Award for Bioanalytical Contract Testing Services.
CorFlow Therapeutics AG announced that the company has completed the CHF 2.6M 1st close of its Seed+ financing round led by experienced private medical device investors who over the last decades have supported breakthrough interventional cardiology technologies.
Eisai Co., Ltd. and Biogen Inc. announced today that the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer's
NANOBIOTIX , a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma.
KalVista Pharmaceuticals, Inc , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors announced that it has entered into a collaboration agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for KVD001, the Company’s investigational intravitreal (IVT) injection candidate currently in development for potential treatment of diabetic macular edema (DME), as well as future oral DME compounds based upon plasma kallikrein inhibition.
Gothenburg in Sweden, a beautiful city with an exciting cultural life will be the destination of the 23rd Congress of the European Association of Hospital Pharmacists (EAHP).
GSK announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Benlysta (belimumab) for the treatment of adult patients with systemic lupus erythematosus (SLE) who are inadequate responders to existing therapies. Benlysta is for use as an add-on therapy in autoantibody positive SLE patients. SLE is a chronic, incurable, autoimmune disease associated with a range of symptoms that can fluctuate over time, affecting almost any system in the body.
Sangamo Therapeutics, Inc. the leader in therapeutic genome editing, and Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for hemophilia and other rare blood disorders, announced today that the U.S.
TrialScope, the global leader in clinical trial transparency and compliance solutions, announced new findings from its sponsor survey on clinical trial results sharing practices, at CBI’s second annual Plain Language Summit in Philadelphia.
Down syndrome is a genetic disorder that results in mental and physical developmental delays. In addition to these disabilities, individuals diagnosed with Down syndrome often develop certain health complications.
Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has completed the expansion of the laboratory facility within its USA headquarters located in the Research Triangle area of North Carolina.
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry announced it has expanded its portfolio of cold chain logistics solutions with the launch of its 'Cryoport. Certified. Cool.' solution, which will be branded as "C3 ™", in support of the new high value regenerative therapies that require temperature-controlled transportation within the 2 - 8°C temperature range during the logistics of processing these new therapies.
Lonza has introduced the CytoSMART™ 2 System, an updated version of Lonza’s popular CytoSMART™ System for live cell imaging. The CytoSMART™ 2 Device features an advanced optical system and more powerful camera unit, which enables researchers to capture higher-resolution images of their cell cultures.
Foreign Secretary Boris Johnson has officially opened TraceLink’s new European headquarters in Uxbridge, UK.
Biotage , a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, is pleased to announce the launch of EVOLUTE® HYDRO, solid phase extraction plates with an integral Hydrolysis capability that enable chemists to perform sample hydrolysis within the extraction plate; saving time and reducing sample transfer issues.
RedHill Biopharma Ltd, a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer announced that it has initiated promotion of Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg(1) in the U.S.
Zavante Therapeutics, Inc., a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients, has signed a Clinical Trial Agreement with the National Institute of Allergy and Infectious Disease (NIAID) to evaluate Zavante’s investigational antibiotic ZOLYD™ (fosfomycin for injection, also known as ZTI-01).
mProve Health, a leading provider of mobile technologies for patient engagement and electronic clinical outcome assessments (eCOA), andGreenphire, the global leader in clinical payment automation, today announceda partnership to provide patients with real-time access to ClinCard payment detailsvia mProve’s engagement app, mPal.
Pfizer Inc. announced that the U.S. Food and Drug Administration approved MYLOTARG™ (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML),
Aquavit Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office has issued a patent for Apollo Technology, System and Method for Personalized Injection Treatment.
Perigord, a Dublin based company specialised in artwork solutions for the pharma and life science industries, recorded 100% growth last year in its software division.
Clinerion has redesigned the web application for Patient Recruitment System, creating a sleek, professional and intuitive new user interface with analytical capabilities.
RedHill Biopharma Ltd. , a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer.
Clinerion has filed an international patent application following the PCT route for a new technology for patient search and identification based on the electronic medical records of patients held by hospitals.
Biovista announced that it is collaborating with HPE to advance Biovista’s Project Prodigy Big Data AI healthcare platform applied in the personalized medicine vertical.
P-MEC China, CPHI china , UBM Sinoexpo,CCCMHPIE,Chinese pharmaceutical market development,Asia’s largest pharma event CPhI and P-MEC China, organised by UBM EMEA, UBM Sinoexpo and China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), closed in June 2017 with a very successful show, reporting positive outlook for further Chinese pharmaceutical market development.
Valeant Pharmaceuticals International, Inc announced it has received a CRL from the U.S. FDA regarding the NDA for latanoprostene bunod ophthalmic solution, 0.024%, an investigative intraocular pressure lowering single-agent eye drop for patients with open angle glaucoma or ocular hypertension.
TrialScope, the global leader in clinical trial transparency and compliance solutions announced the launch of its newest solution, Core Disclosure. Promoting a new level of data efficiency accuracy and alignment, Core Disclosure enables teams to approve disclosure content once and then reuse the disclosure data around the globe.
Başkent University’s hospital cluster is joining the Patient Recruitment System platform, giving their 4.5 M patients access to innovative treatments and therapies offered by cutting edge clinical research.
Now available on all new laboratory autoclaves and research grade sterilisers leaving the Priorclave production where a printer is required will benefit from inclusion of a new thermal printer.
RedHill Biopharma Ltd. , a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today reported, following a second pre-planned meeting to assess the safety and efficacy data from its ongoing first Phase III study with RHB-104 for Crohn’s disease (the MAP US study) by an independent Data and Safety Monitoring Board (DSMB), that it has received a unanimous positive recommendation from the DSMB to continue the study as planned.
Teva Pharmaceutical Industries Ltd. announced the launch of generic Epiduo®1 (adapalene and benzoyl peroxide) gel, 0.1%/2.5% in the U.S.
Gilead Sciences, Inc announced that the European Commission has granted marketing authorization for Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg), as a once-daily single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.
Orchard Therapeutics Limited , a clinical-stage biotechnology company dedicated to bringing transformative autologous ex-vivo gene therapies to patients with rare diseases of high unmet medical need is delighted to announce that the US FDA granted a Rare Paediatric Disease Designation to OTL-101.
MEDICAL FAIR THAILAND 2017 will be its largest edition yet, with booth space fully sold out since May, featuring 700 exhibitors from 45 countries including 18 National Pavilions and country groups on a show floor that has expanded by 20% compared to 2015, at the Queen Sirikit National Convention Center. Held biennially, MEDICAL FAIR THAILAND 2017 confirms its position as Thailand’s most prominent trade fair through dynamic sales, wide range of product and services and high-quality line-up of signature conferences and seminars.
Amgen and Array BioPharma announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders.
Two industry innovators are joining forces to take the lead in real-world studies. Clinerion and Cisiv have formed a groundbreaking partnership to offer a revolutionary approach to observational research by enabling automated data transfer from electronic hospital records (EHRs) to electronic data capture (EDC).
Quanticate has completed an investment initiative to upgrade its pharmacovigilance safety database and its in-house technology platform in preparation for the upcoming Article 2(3) of Directive 2010/84/EU that will impact the pharmaceutical industry later this year.
Eisai Co., Ltd. announced that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic name: lenvatinib mesylate) for the treatment of hepatocellular carcinoma (HCC) in Japan, the first in the world.
Lannett Company Inc announced that it received approval from the U.S. FDA of its Abbreviated New Drug Application (ANDA) for Niacin Extended-Release Tablets USP, 500 mg and 1000 mg, the therapeutic equivalent to the reference listed drug, Niaspan® Extended-Release Tablets, 500 mg and 1000 mg, of AbbVie Inc.
Thermo Fisher Scientific Inc., the world leader in serving science, announced new technologies that are designed to allow analytical chemists to obtain high-resolution separations with outstanding sensitivity and reproducibility.
At the upcoming edition of Vitafoods Asia in Singapore, Asia Pacific’s nutraceutical industry will gather at the annual event to do business, uncover the latest product innovations, and to learn more about the market and its best practices.
TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced that it will relocate its European headquarters to a larger, newly renovated office space in Uxbridge, UK.
interpack 2017, the Olympics of the global processing and packaging industry, is well under way in the beautiful city of Düsseldorf on the Rhine. Shanghai World of Packaging (swop), as a member of interpack alliance, used this great opportunity to present itself to more than 200,000 professionals and business men from all over the world.
TraceLink Inc., the world’s largest track and trace network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes unveiled an industry first: an integrated Compliance and Digital Information Platform for pharmacies with EU Falsified Medicines Directive (FMD) requirements.
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer announced that the Company and an affiliate of Sanofi have amended their license agreements covering all compounds in development by Sanofi using ImmunoGen's technology.
The Health Industry Summit (tHIS) 2017 hosted by China and organized by Reed Sinopharm, opened in Shanghai at the National Exhibition and Convention Center on May 15th with well over two hundred thousand healthcare industry professionals from more than 150 countries and regions in attendance.
BayWa r.e. will again take centre stage at Intersolar Europe in Munich. This year the company invites visitors to stand A3.175, A3.180 to attend a wide-ranging lecture programme which will look at key issues driving the market, new product innovations and what the future has in store.
Biotage ,a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, is pleased to announce the launch of Isolera™ Dalton 2000, a new mass detector for flash purification that expands functionality through a wider detection range of ion masses, up to m/z 2000, and new analysis features.
Clinerion launches a seminar event in São Paulo to introduce cutting-edge tools and technologies for the acceleration of clinical research.
Glenmark Pharmaceuticals Limited in association with Americares India Foundation has initiated a week long awareness campaign on ‘Hypertension’ from May 15, 2017 to May 19, 2017 in Mumbai.
Aptar Pharma, a world leader in innovative drug delivery systems, is pleased to announce the approval by the EMA of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG.
If you have ever been involved in a clinical study or thought about it, you might want to take a little bit of time to learn more about the process.
Innovation is the focus in 2017, as Videojet showcases four brand new products from three technologies at Interpack designed to deliver maximum uptime, unprecedented reliability and attractive total cost of ownership figures.
Aldeyra Therapeutics, Inc. , a clinical-stage biotech company devoted to treating diseases thought to be related to endogenous aldehydes.
Oramed Pharmaceuticals Inc (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that the European Patent Office has granted the Company a patent titled, “Methods and Compositions for Treating Diabetes:
To supportglobal food manufacturers in meeting the documentation and active managerial control requirements of the Food Safety Modernisation Act (FSMA).
Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases.
DiscoverX Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development announced their partnership with B’SYS GmbH to expand DiscoverX’s SAFETYscan in vitro pharmacological profiling services for ion channel assays.
Hardware Tools Middle East looks ahead to a successful 2017 edition, with interest from hardware and tools manufacturers continuing, as market sentiments begin to stabilise across the region.
Following a £0.5m Medical Research Council (MRC) grant to implement new Positron Emission Tomography (PET) imaging tracers for mitochondrial dysfunction and synaptic loss.
AstraZeneca announced that the US FDA has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR TKI therapy.
Botanix Pharmaceuticals is pleased to announce that the US Drug Enforcement Agency (DEA) has approved the export, and the Australian Office of Controlled Substances (ODC) has approved the import of synthetic cannabidiol for Botanix’s planned clinical studies.
Citius Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that it has recently concluded negotiations to add South America to its worldwide license for Mino-Lok™.
Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser is available for patients in the U.S. prescription market for the first time with Allergan’s RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%.
Recipharm, the contract development and manufacturing organisation (CDMO), has entered into a long term agreement with Sato Pharmaceutical Co. for the commercial manufacture and delivery of Emla Patch to Japan.
X-Chem, Inc. , a privately held biotechnology company applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc.
Acura Pharmaceuticals, Inc. and MainPointe Pharmaceuticals, LLC announced that they have entered into a License Agreement (the "Agreement") to have MainPointe exclusively market NEXAFED and NEXAFED Sinus in the US and Canada.
Provepharm, a French company specialized in the development of pharmaceutical applications announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA
Patheon is to showcase its biologic, small molecule API development services and manufacturing capabilities for finished dosage forms at CPhI / ICSE Worldwide from Tuesday 7 October to Thursday 9 October in Paris Nord Villepinte, France.
The U.S. FDA has approved Humalog® 200 units/mL KwikPen, a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin.
The U.S. FDA accepted a supplemental New Drug Application for Jardiance based on cardiovascular risk reduction data from the landmark EMPA-REG OUTCOME® trial.
Mersana Therapeutics and Takeda Pharmaceutical Company Limited announced that they have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the United States and Canada
Novartis announced that the United States FDA approved Afinitor® tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.
Eli Lilly and Company announced today that the U.S. FDA has approved Taltz® injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Alexion Pharmaceuticals, Inc announced that Japan’s Ministry of Health, Labour and Welfare has approved Kanuma for the treatment of patients of all ages in Japan with lysosomal acid lipase deficiency.
At Interpack 2017, Bosch Packaging Technology presents its latest solutions for solid pharmaceuticals. According to Christian Treitel, head of pharma business development at Bosch Packaging Technology.
Innovation Network Corporation of Japan Takeda Pharmaceutical Company Limited , and MEDIPAL HOLDINGS CORPORATION have agreed to jointly invest a total of 10 billion yen to establish a new company, which will be named SCOHIA PHARMA, Inc.
Precision NanoSystems has launched the NanoAssemblr™ Scale-Up system to support the clinical development of nanomedicines.
At Interpack 2017, Bosch Packaging Technology presents new developments from its comprehensive portfolio for liquid pharmaceuticals.
Clinerion announces the expansion of its activities into countries in Eastern Europe, the Middle East and Africa (EEMEA), spearheaded by a newly appointed regional head.
aTyr Pharma, Inc , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases announced that the EMA has granted orphan drug designation to Resolaris™ for the treatment of LGMD patients.